Provider: Wright Reports
Actelion Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Auxilium Pharmaceuticals, Inc. And Actelion Pharmaceuticals Ltd. Enter Collaboration Agreement For XIAFLEX In Canada, Australia, Brazil And Mexico
Auxilium Pharmaceuticals, Inc. and Actelion Ltd announced that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX (collagenase clostridium histolyticum), a first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease. Under the terms of the agreement, Actelion will receive exclusive rights to commercialize XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Canada, Australia, Brazil and Mexico upon receipt of the respective regulatory approvals. Actelion will be primarily responsible for the applicable regulatory and commercialization activities for XIAFLEX in these countries. Under the terms of the agreement, Actelion will pay Auxilium $10 million upfront and will also make up to $16 million in potential regulatory, pricing and reimbursement payments and $42.5 million in potential sales payments. Auxilium will also receive increasing tiered double-digit royalties based on sales of XIAFLEX in Actelion' territories and will supply product to Actelion at a predetermined cost. Auxilium will remain primarily responsible for the global development of XIAFLEX in Peyronie's disease and will be responsible for all clinical and commercial drug manufacturing and supply. Actelion will be responsible for clinical development activities and associated costs corresponding to any additional trials required for specific territories.
Latest Developments for Actelion Ltd
- Actelion Ltd Receives US FDA Approval Of Opsumit For The Treatment Of Pulmonary Arterial Hypertension
- Actelion Ltd Closes Acquisition Of Privately-held Ceptaris Therapeutics
- Actelion Ltd Raises FY 2013 EPS Guidance; Updates FY 2014 EPS Guidance; Lowers FY 2015 EPS Guidance-DJ
- Actelion Ltd Issues FY 2013 EPS Guidance Above Analysts' Estimates; Comments On FY 2014 And FY 2015 EPS Guidance-Conference Call
Latest Key Developments in Biotechnology
- Share this
- Digg this